Four promising Swiss start-ups pitched their ventures from the HEMEX Incubator to an online group of investors. 

 

LiVET develops and produces rapid molecular point-of-care diagnostic tests for veterinary use. Based on their proprietary platform technology, veterinarians are able to diagnose infectious diseases on-site and within only 30 minutes for up to 16 samples at once. This allows for immediate and specific treatment. Their first multiplex panel test for respiratory diseases in horses will be available by summer 2020. LiVET aims to change the way of thinking about diagnostics in the veterinary market, implementing point-of care testing as the new standard. By bringing the application of specialized laboratories closer to the patient, we strive to increase the quality of animal health care.

 

Hi-D Imaging, an ETH Zurich medtech spin-off, aims to revolutionize the cardiovascular sector by making personalized heart valve replacement therapy a reality. The diverse team of engineers and cardiologists of Hi-D Imaging  applies high-precision fluid dynamics analysis and machine learning algorithms to develop the world’s first AI-based pre-operational planning platform that assesses full hemodynamics in patient-specific anatomies, offered as Software-as-a-Service (SaaS).  

 

Mathias Wipf of MOMM Diagnostics in laboratoryMOMM Diagnostics is an Empa (Eidgenössische Materialprüfungs- und Forschungsanstalt, Swiss Federal Laboratories for Materials Science and Technology) spin-off developing point-of-care diagnostic tests for preeclampsia (PE). PE is a pregnancy disorder that can have devastating effects on the health of the mother and the unborn baby. When detected at an early stage using MOMM’s patented technology, it is possible to save the lives of the mother and her unborn child.

BigOmics is a data analytics start-up that aims to democratize biodata analysis in digital health to accelerate scientific discoveries in medicine. It solves the data analysis bottleneck by bringing life scientists closer to their data and enabling self-service analytics. With its easy-to-use platforms, BigOmics empowers biologists to analyze their data themselves faster, simpler and better.

 

 

Interested in becoming an early-stage investor in one of these promising start-ups or do you want to be kept informed about their progress and future funding rounds / pitch events?

Please contact our start-up scout Franziska Stemmler at +41 61 927 28 02 or franziska.stemmler@hemex.ch

 

About HEMEX

HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its main focus to bring innovative drugs, medical devices and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding. More at https://hemex.eu/

Leave a Reply

Your email address will not be published. Required fields are marked *